About Valneva

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company has commercialized three vaccines, including a single shot chikungunya vaccine, and advanced vaccine candidates through clinical development for Lyme disease, Shigella and Zika. With over 700 employees across six countries, Valneva combines proven product development capabilities with an integrated business model. The company focuses on utilizing validated scientific approaches to advance late stage clinical programs toward regulatory approval and commercialization, aiming to become first, best or only in class.